Draw/line
Education and research purposes only, not medical advice. Unapproved compounds are not for human consumption. Check every result with your prescriber. Disclaimer Research and education only. Not medical advice. Disclaimer
Home / Compounds / Thymosin Alpha 1

Thymosin Alpha 1

Thymosin alpha 1 (thymalfasin, Zadaxin): where it is approved, why it is not approved in the US, what large trials showed, and the known side effects.

Not FDA-approved, approved abroad · Evidence grade B · Reviewed

Not approved by the FDA for human use. Not for human consumption. This page describes Thymosin Alpha 1 only to explain its regulatory status, what has been studied and its known risks. Drawline does not recommend obtaining or using it. Disclaimer

2026 update2026: FDA moved several withdrawn nominations, including Semax, Selank, DSIP and thymosin alpha 1, to a table of withdrawn nominations while keeping its safety notes. Leaving the safety-risk list does not make a substance approved or eligible for compounding.See every change in the 2026 tracker ›
Approved and studied uses
  • Not approvedImmune supportApproved in some other countries; not approved in the US
  • Not approvedHepatitis BFDA orphan designation since 1991, not approval

Thymosin Alpha 1 (TA1, thymalfasin, Zadaxin). Immune peptide.

BNot FDA-approved, approved abroad. Evidence grade B: human trials, narrow or pending approval.

What is Thymosin Alpha 1?

Thymosin alpha 1 is a 28-amino-acid peptide made by the thymus gland. Thymalfasin is a lab-made copy, sold abroad as Zadaxin to support the immune system.

Is Thymosin Alpha 1 FDA-approved?

Not approved in the United States, Japan or most of Europe. It has held an FDA orphan designation for chronic hepatitis B since 1991 without approval. Its developer reports approval in more than 30 countries for hepatitis B and C and as an add-on during chemotherapy; FDA says it cannot verify those claims. In December 2024 an FDA advisory committee voted against adding it to the list of substances pharmacies may compound. FDA had listed it among bulk substances that may present significant safety risks in compounding. The nomination was later withdrawn, and in 2026 FDA moved it to a table of withdrawn nominations while keeping its safety notes. Leaving that list does not make it approved or eligible for compounding.

What does the evidence show for Thymosin Alpha 1?

A large double-blind trial in 1,106 adults with sepsis, published in 2025, found no difference in 28-day deaths (23.4% with it, 24.1% with placebo). A 2026 Cochrane review of 10 hepatitis B trials found the evidence of any benefit to be of very low certainty. COVID-19 studies did not show fewer deaths.

What are the known risks of Thymosin Alpha 1?

In the labeling used abroad, the main side effect is discomfort at the injection site, with rare rash, joint pain and swelling. It is not for people who are allergic to it or who take drugs to suppress the immune system, such as transplant recipients. The sepsis trial found no difference in side effects. Sport: it is not named on the World Anti-Doping Code Prohibited List. The list also bans unapproved substances in general, and from 2027 names unapproved peptides there, so athletes should check with their anti-doping agency.

How is Thymosin Alpha 1 measured?

Usually supplied as a powder vial. The Mix mode converts a prescribed dose into syringe units. Products sold online as "research use only" have no assurance of identity, dose or sterility. The calculator can do the arithmetic for any vial, but it cannot tell you what is actually in one.

Sources: FDA: orphan designation record for thymalfasin; FDA: thymosin alpha 1 presentation, December 2024; FDA: advisory committee minutes, December 2024; FDA: bulk drug substances that may present significant safety risks; Wu et al., thymosin alpha 1 in sepsis, BMJ (2025); Cochrane review, thymosin alpha 1 for hepatitis B (2026); COVID-19 meta-analysis (2023); Zadaxin prescribing information; WADA: 2026 Prohibited List; USADA: athlete advisory on the 2027 Prohibited List. This profile does not recommend any dose or use.

For research and educational use. Not medical advice. Regulatory status changes, so confirm the current position with FDA or a licensed professional.

Spot a mistake or an out-of-date fact? Report an error. We check every report against the sources.